2019 Metastatic Hormone Refractory Prostate Cancer Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 464 pages | ID: 24664ED9052EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Metastatic Hormone Refractory Prostate Cancer Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Metastatic Hormone Refractory Prostate Cancer. It presents in-depth analysis of Metastatic Hormone Refractory Prostate Cancer clinical trials across markets and companies. The research work is for providing complete understanding into trends in Metastatic Hormone Refractory Prostate Cancer.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Metastatic Hormone Refractory Prostate Cancer clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Metastatic Hormone Refractory Prostate Cancer

The research work is prepared through extensive and continuous research on Metastatic Hormone Refractory Prostate Cancer trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Metastatic Hormone Refractory Prostate Cancer patients are identified
• The report includes panorama of Metastatic Hormone Refractory Prostate Cancer clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Metastatic Hormone Refractory Prostate Cancer clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Metastatic Hormone Refractory Prostate Cancer Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Region
  2.2.2 Average Enrollment of Metastatic Hormone Refractory Prostate Cancer Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Metastatic Hormone Refractory Prostate Cancer Treatment, 2019

3. REGION WISE METASTATIC HORMONE REFRACTORY PROSTATE CANCER CLINICAL TRIALS

3.1 Asia Pacific Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Country
3.2 Europe Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Country
3.3 North America Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Country
3.4 Middle East and Africa Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Country
3.5 South and Central America Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Country

4. METASTATIC HORMONE REFRACTORY PROSTATE CANCER CLINICAL TRIAL TRENDS

4.1 Start Year wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials
4.2 Phase wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials
4.3 Trial Status wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials
4.4 Trial Type wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials

5. METASTATIC HORMONE REFRACTORY PROSTATE CANCER AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Metastatic Hormone Refractory Prostate Cancer Trials by Year
5.2 Average Enrollment in Metastatic Hormone Refractory Prostate Cancer Trials by Phase
5.3 Average Enrollment in Metastatic Hormone Refractory Prostate Cancer Trials by Status
5.4 Average Enrollment in Metastatic Hormone Refractory Prostate Cancer Trials by Type of Trial

6. COMPANIES PARTICIPATING IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER CLINICAL TRIALS

6.1 Metastatic Hormone Refractory Prostate Cancer Trials by Sponsor Type
6.2 Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Metastatic Hormone Refractory Prostate Cancer Trials- Phase
7.2 Metastatic Hormone Refractory Prostate Cancer Trials- Phase
7.3 Metastatic Hormone Refractory Prostate Cancer Trials- Phase
7.4 Metastatic Hormone Refractory Prostate Cancer Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Figure 5: Europe – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Figure 7: North America – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Figure 9: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Phase
Figure 10: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Trial Status
Figure 11: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Type
Figure 12: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Sponsor Type
Figure 13: Metastatic Hormone Refractory Prostate Cancer Clinical Trials by Leading Sponsors
Figure 14: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Phase
Figure 15: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Trial Status
Figure 16: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Type
Figure 17: Metastatic Hormone Refractory Prostate Cancer- Average Enrolment by Type of Sponsors
Figure 18: Metastatic Hormone Refractory Prostate Cancer- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Metastatic Hormone Refractory Prostate Cancer Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Table 5: Europe – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Table 7: North America – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Metastatic Hormone Refractory Prostate Cancer Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Phase
Table 15: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Trial Status
Table 16: Metastatic Hormone Refractory Prostate Cancer Average Enrollment by Type
Table 17: Metastatic Hormone Refractory Prostate Cancer- Average Enrolment by Type of Sponsors
Table 18: Metastatic Hormone Refractory Prostate Cancer- Enrolment by Leading Sponsors